دورية أكاديمية
أعرض في EDS

Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma.

التفاصيل البيبلوغرافية
العنوان: Potential role of serum mesothelin in predicting survival of patients with malignant pleural mesothelioma.
المؤلفون: Fontana V; Clinical Epidemiology Unit, IRCCS Ospedale Policlinico San Martino, I-16132 Genova, Italy., Pistillo MP; Tumor Epigenetics Unit, IRCCS Ospedale Policlinico San Martino, I-16132 Genova, Italy., Vigani A; Department of Oncology, Azienda Sanitaria Locale 5, I-19124 La Spezia, Italy., Canessa PA; Department of Pneumology, Azienda Sanitaria Locale 5, I-19124 La Spezia, Italy., Berisso G; Department of Medicine, Azienda Sanitaria Locale 5, I-19124 La Spezia, Italy., Giannoni U; Department of Radiodiagnosis, Azienda Sanitaria Locale 5, I-19124 La Spezia, Italy., Ferro P; Department of Histopathology and Cytopathology, Azienda Sanitaria Locale 5, I-19124 La Spezia, Italy., Franceschini MC; Department of Histopathology and Cytopathology, Azienda Sanitaria Locale 5, I-19124 La Spezia, Italy., Carosio R; Tumor Epigenetics Unit, IRCCS Ospedale Policlinico San Martino, I-16132 Genova, Italy., Tonarelli M; Department of Histopathology and Cytopathology, Azienda Sanitaria Locale 5, I-19124 La Spezia, Italy., Dessanti P; Department of Histopathology and Cytopathology, Azienda Sanitaria Locale 5, I-19124 La Spezia, Italy., Roncella S; Department of Histopathology and Cytopathology, Azienda Sanitaria Locale 5, I-19124 La Spezia, Italy.
المصدر: Oncology letters [Oncol Lett] 2021 Feb; Vol. 21 (2), pp. 128. Date of Electronic Publication: 2020 Dec 18.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Spandidos Publications] Country of Publication: Greece NLM ID: 101531236 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1792-1074 (Print) Linking ISSN: 17921074 NLM ISO Abbreviation: Oncol Lett Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Athens : Spandidos Publications]
مستخلص: Malignant pleural mesothelioma (MPM) is an aggressive tumor with poor survival rates. Therefore, it is essential to have effective biological markers predicting the course of the disease and prognosis. The aim of the present study was to highlight the prognostic significance of serum soluble mesothelin-related protein (Se-SMRP) in patients with MPM at diagnosis. Se-SMRP was determined in 60 patients using an ELISA commercial kit. Se-SMRP levels were subdivided into three tertile-based categories and in each category overall survival (OS) indexes were determined using the Kaplan-Meier and Cox regression analyses. The association between Se-SMRP levels and OS was also assessed by restricted cubic spline (RCS) analysis. No notable differences in the Kaplan-Meier probabilities were identified across the Se-SMRP categories (<0.66 nM, 0.66-1.46 nM, >1.46 nM) although an upward trend in death rate ratios (RR) was pointed out by comparing the higher (RR=1.95) and intermediate (RR=1.86) categories with the lower category (RR=1.00). In addition, such an increasing tendency, particularly when the biomarker exceeded 1.0 nM, was confirmed by an RCS function of Se-SMPR levels fitted to survival data using the Cox regression equation. The present study provided evidence in favor of a prognostic value of Se-SMRP in patients with MPM.
(Copyright © 2020, Spandidos Publications.)
References: Oncotarget. 2017 Jul 11;8(28):46425-46435. (PMID: 28507279)
Clin Cancer Res. 2011 Mar 1;17(5):1181-9. (PMID: 21177406)
J Thorac Oncol. 2008 Nov;3(11):1317-24. (PMID: 18978568)
Int J Cancer. 2012 May 1;130(9):2146-54. (PMID: 21647880)
J Thorac Oncol. 2016 Jun;11(6):900-9. (PMID: 26903362)
Anticancer Res. 2013 Jun;33(6):2707-13. (PMID: 23749930)
BMC Cancer. 2014 Sep 17;14:674. (PMID: 25227779)
Arch Pathol Lab Med. 2012 Mar;136(3):277-93. (PMID: 22372904)
Respir Med. 2010 Jan;104(1):149-56. (PMID: 19945835)
Thorax. 2007 Jul;62(7):569-76. (PMID: 17356060)
Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):136-40. (PMID: 8552591)
Am J Respir Crit Care Med. 2009 May 15;179(10):950-4. (PMID: 19201924)
Front Oncol. 2019 Aug 14;9:740. (PMID: 31475103)
Nat Rev Cancer. 2017 Jul 25;17(8):475-488. (PMID: 28740119)
Clin Cancer Res. 2007 Sep 1;13(17):5076-81. (PMID: 17785560)
Int J Biol Markers. 2011 Jul-Sep;26(3):160-5. (PMID: 21928246)
Chest. 2012 Feb;141(2):477-484. (PMID: 21737491)
Recent Results Cancer Res. 2011;189:45-55. (PMID: 21479895)
Clin Cancer Res. 2007 May 15;13(10):2928-35. (PMID: 17504993)
J Clin Oncol. 2016 Dec;34(34):4171-4179. (PMID: 27863199)
Eur Respir Rev. 2016 Dec;25(142):472-486. (PMID: 27903668)
Thorax. 2014 Oct;69(10):895-902. (PMID: 25037982)
J Thorac Dis. 2018 Jun;10(Suppl 17):S1956-S1961. (PMID: 30023090)
J Thorac Oncol. 2018 Aug;13(8):1189-1203. (PMID: 29723687)
Thorax. 1990 Sep;45(9):649-54. (PMID: 2218970)
Cancer Discov. 2016 Feb;6(2):133-46. (PMID: 26503962)
Nat Genet. 2016 Apr;48(4):407-16. (PMID: 26928227)
Br J Cancer. 2017 Mar 14;116(6):731-741. (PMID: 28170372)
J Thorac Oncol. 2019 Oct;14(10):1704-1717. (PMID: 31260832)
Anticancer Res. 2019 Sep;39(9):5219-5223. (PMID: 31519636)
J Thorac Oncol. 2019 May;14(5):e92-e94. (PMID: 31027749)
Biomark Res. 2019 Aug 23;7:18. (PMID: 31463062)
Lung Cancer. 2011 Oct;74(1):55-60. (PMID: 21397972)
Ann Cardiothorac Surg. 2012 Nov;1(4):491-6. (PMID: 23977542)
J Thorac Oncol. 2016 Feb;11(2):249-55. (PMID: 26845118)
Br J Cancer. 2014 Oct 28;111(9):1860-9. (PMID: 25188323)
Cancer Epidemiol Biomarkers Prev. 2020 Dec;29(12):2524-2540. (PMID: 32699075)
BMC Cancer. 2017 Mar 23;17(1):212. (PMID: 28335760)
Front Oncol. 2018 Dec 21;8:650. (PMID: 30622932)
فهرسة مساهمة: Keywords: mesothelin; mesothelioma; prognosis; serum; survival
تواريخ الأحداث: Date Created: 20210208 Latest Revision: 20210210
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC7798108
DOI: 10.3892/ol.2020.12389
PMID: 33552249
قاعدة البيانات: MEDLINE
الوصف
تدمد:1792-1074
DOI:10.3892/ol.2020.12389